ANN ARBOR, Mich. (AP) — ANN ARBOR, Mich. (AP) — Esperion Therapeutics Inc. (ESPR) on Thursday reported a loss of $29.5 million in its third quarter.
The Ann Arbor, Michigan-based company said it had a loss of 15 cents per share.
The results did not meet Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 14 cents per share.
The biopharmaceutical company posted revenue of $51.6 million in the period, also missing Street forecasts. Four analysts surveyed by Zacks expected $55.4 million.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on ESPR at https://www.zacks.com/ap/ESPR
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。